Uri Lopatin - Assembly Biosciences Insider

Assembly Biosciences Inc -- USA Stock  

USD 30.89  0.32  1.03%

Vice President - Research & Development, Chief Medical Officer

Dr. Uri Lopatin, M.D. is Vice President Research Development, Chief Medical Officer of ASSEMBLY BIOSCIENCES, Inc. At Assembly Pharmaceuticals, he was Chief Medical Officer and Vice President Research and Development, a position he held since October, 2012. Prior to that, he was a Senior Director for Clinical and Translational ResearchLiver Disease at Gilead Sciences from October, 2010 to September, 2012, a Translational Medical Leader at Roche from May, 2008 to September, 2010. He has designed and coordinated preclinical and clinical collaborations, as well as phase I through IV clinical studies of multiple new molecular entities. Dr. Lopatin has published extensively, especially on hepatitis B and immunology and is an author of multiple patents in the field of treatment and diagnosis for viral hepatitis. Dr. Lopatin received his infectious disease Board certification following fellowship training in ID at the NIH, and internal medicine board certification following completion of residency at NYU. He received his MD in 2000 from University of Medicine and DentistryNew Jersey Medical School.
Age: 42  President Since 2014  Ph.D    
646 706-5208  www.ventrusbio.com
Lopatin received his infectious disease Board certification following fellowship training in ID at the NIH, and internal medicine board certification following completion of residency at NYU. He received his MD in 2000 from University of Medicine and DentistryNew Jersey Medical School, where he was the recipient of the Stanley S Bergen medal of excellence. He holds a BA in biology from Cornell University, where he graduated cum laude with distinction in all subjects.

Uri Lopatin Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (26.59) % which means that it has lost $26.59 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (64.48) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Entity Summary

Assembly Biosciences, Inc., a biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus infection and to restore health to a dysbiotic microbiome in the United States. Assembly Biosciences Inc (ASMB) is traded on Nasdaq Capital Markets in USA. It is located in NEW YORK, U.S.A and employs 65 people. Assembly Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Correlation Analysis Now
   

Correlation Analysis

Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Hide  View All  Next  Launch Correlation Analysis
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Assembly Biosciences Inc to your portfolio

Top Management

Assembly Biosciences Inc Leadership Team
Adam Zlotnick, Founder
Uri Lopatin, President, Ph.D
Myron Holubiak, Director
Lee Arnold, Executive, Ph.D
Anthony Altig, Director
Richard Colonno, Executive
William Ringo, Chairman, MBA
Richard DiMarchi, Director, Ph.D
Miguel Barbosa, Executive, Ph.D
Mark Auerbach, Director
Derek Small, CEO
Alan Lewis, Director, Ph.D
David Barrett, COO

Stock Performance

Assembly Biosciences Performance Indicators